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© 2011 Japanese Society of Tropical Medicine Abstract: Dengue fever (DF) and dengue hemorrhagic fever (DHF) are mosquito-transmitted diseases of global
importance. Despite significant research efforts, no approved vaccines or antiviral drugs against these diseases are
currently available. This brief article reviews the status of dengue vaccine development, with particular emphasis
on the vaccine strategies in more advanced stages of evaluation; these include traditional attenuation, chimerization
and engineered attenuation. Several aspects of these vaccine design strategies, including concerns about vaccine
candidates inducing infection-enhancing antibodies, are also presented.
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INTRODUCTION
Diseases caused by dengue virus infections are an
increasing problem worldwide because of current globaliza-
tion trends [1, 2]. Despite intense research efforts over more
than 30 years, no dengue vaccine is commercially available
[3–10]. Approved antiviral drugs are also unavailable to
treat dengue diseases. Currently, management of dengue
virus infections relies on control measures targeting
mosquito vectors. However, the emergence of mutant vector
strains acquiring resistance against insecticides is an ongoing
problem [11–13].
This paper briefly reviews efforts to develop a dengue
vaccine. Currently, three vaccine strategies, namely tradi-
tional attenuation, chimerization and engineered attenua-
tion, are in advanced stages of evaluation. After giving an
overview on virus and gene structure, epidemiology, trans-
mission and pathogenesis, several aspects of these vaccine
strategies are presented. Other vaccine strategies, including
virus-vectored, pseudo-infectious virus, DNA, inactivated
and subunit vaccines developed for dengue viruses, have
been described elsewhere [3–10].
DENGUE VIRUS STRUCTURE AND GENOME
Four types of dengue virus (dengue type 1 to 4 viruses;
DENV1 to DENV4) belong to the genus Flavivirus of the
family Flaviviridae [14]. The flavivirus virion consists of a
nucleocapsid structure surrounded by a lipid bilayer con-
taining an envelope (E) glycoprotein and a non-glycosylated
membrane (M) protein. The nucleocapsid is composed of a
capsid (C) protein and a single strand of positive-sense
RNA. The E protein is the major surface protein with a role
in receptor binding and membrane fusion, and it is known to
constitute a major immunogen during flavivirus infection.
Specifically, E protein contains most of the sites that react
with neutralizing antibodies as well as many protective
epitopes. The M protein is found in infected cells as a
glycosylated precursor, premembrane (prM) protein. Dengue
viral proteins, including these three structural proteins, are
encoded by a single long translational open reading frame
present in the genomic RNA. These viral proteins are
synthesized in the order of C, prM, E, followed by non-
structural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B
and NS5. The open reading frame is flanked by untranslated
regions, the 5'-UTR and the 3'-UTR.
The similarity in antigenic structure among the four
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types of DENV is closely related to the characteristic
features of the manifestations of dengue diseases. Most
members of the genus Flavivirus can be grouped into eight
antigenic complexes and four dengue viruses belong to the
dengue virus serocomplex. These four dengue viruses are
antigenically cross-reactive. Homology in the amino acid
sequence of the E protein is approximately 70% among
DENV1–4 [15].
EPIDEMIOLOGY
DENV1–4 are responsible for dengue fever (DF) and
dengue hemorrhagic fever (DHF). These diseases occur
throughout most of the tropical and subtropical areas of the
world, with an estimated 50–100 million cases of DF and
250–500 thousand cases of DHF reported annually [1, 2].
DF and DHF are endemic in at least 100 countries and >2.5
billion people are at risk of infection.
In non-endemic areas, dengue infections may result
from imported infectious cases [16]. An individual who has
traveled and acquired an infection in an endemic area may
return to their home country (non-endemic area) within an
intrinsic period and then manifest symptoms. For example,
DENVs do not currently circulate in Japan but approximately
1.7 million people travel overseas every year, increasing
the risk of imported dengue infections [17]. According to a
report from the National Institute of Infectious Diseases,
around 100 virologically confirmed cases of dengue virus
infection have been detected annually in recent years:
however in 2010, 215 cases have been reported until the end
of October [18]. This raises concerns that there are a large
number of viremic patients in Japan and that these infecting
viruses may be transmitted to domestic mosquitoes via
mosquito bites during the summer season.
Phylogenetic analyses of the nucleotide sequences of
the E coding region in the genome of isolated viruses
demonstrate that several genotypes exist within each of the
DENV types, DENV1–4 [19]. In addition to evolving within
a particular environment, viruses may be transported from
other areas and introduced into new environments because
of the frequent movement of human hosts, both domestically
and internationally. If the novel virus is better adapted to
survive and propagate in its new environment, this virus
may dominate over previously circulating viruses in the
area. The replacement of a lineage, genotype or even a virus
type has been reported in several areas [20–26].
TRANSMISSION
DENV exists in a transmission cycle between monkeys/
humans and mosquito vectors. In urban settings, humans
have a role in the amplification of the viruses and their
transmission cycles [27]. Although Aedes aegypti and Aedes
albopictus are the major vectors for dengue virus transmis-
sion, the former is the more important vector because it has
adapted to inhabit human dwellings. Patients can show
serum virus titers up to 7 log10 PFU/ml [28, 29], which is
high enough to infect mosquitoes when they ingest a blood
meal (approximately 2 μl). In sylvatic settings, monkeys are
considered an amplification host, transmitting the virus to
mosquitoes.
Transovarial transmission is another mechanism by
which the virus is maintained in nature. In susceptible
mosquitoes, the first organ to allow virus replication is the
midgut. The viral offspring released from the cells of the
midgut into the body lumen may disseminate to most organs/
tissues of the mosquito, including the salivary gland, allowing
direct transmission of the virus to humans. The virus may
also be disseminated to the ovary of the mosquito, allowing
transmission of the virus to their eggs. Therefore, the next
generation may possess the virus without bloodsucking and
may potentially be competent to transmit the virus to humans
at first bite. This transmission mechanism has been demon-
strated in the laboratory [30, 31] and in the field [32–35].
PATHOGENESIS
Most infections with dengue virus are asymptomatic.
Clinical cases usually take a benign form (DF) and occa-
sionally a severe form (DHF) [1, 2]. DF patients develop
high fever, headache and muscle and joint pain, from which
almost all cases recover, whereas DHF patients develop
mainly plasma leakage and hemorrhagic manifestations,
which may lead to shock. The case-fatality rate of DHF can
exceed 20% without proper treatment, and a large propor-
tion of hospitalized patients are children [36].
Several hypotheses have been proposed regarding the
mechanism of increased disease severity from DF to DHF,
which include both host and viral factors [1, 2, 37, 38]. As
described above, the four DENVs are antigenically cross-
reactive. Many host factors are involved in the immune
response after initial infection. Cross-reactive memory T
cells are closely related to increased disease severity, and
increased levels of cytokines and chemokines are also
associated with the secondary infection. The genetic back-
ground of the host has also been proposed to be a factor
involved in disease severity. Viral factors are attributed to
the nucleotide sequence differences between viruses isolated
from mild (DF) and severe (DHF) forms of the disease.
Although several mechanisms have been proposed for
dengue pathogenesis, it is generally accepted that higher
levels of viremia correspond to increased disease severity65 E. Konishi
[39–41]. One of the mechanisms increasing the viremia
level is antibody-dependent enhancement (ADE) of infec-
tion [42, 43], which is mediated by Fc gamma receptors
(FcγRs) on monocytes/macrophages in the presence of
cross-reactive non-neutralizing (enhancing) antibodies [44].
In contrast, neutralizing antibodies are widely believed to
reduce viremia levels [45, 46]. Thus, the viremia level
depends on the balance of both neutralizing and enhancing
antibodies and may determine the outcome of the disease;
that is, by providing protection when neutralizing activities
are higher than enhancing activities and conferring deterio-
ration when enhancing activities are higher than neutraliz-
ing activities.
VACCINES
In the preclinical stages, the effectiveness of vaccine
candidates has been evaluated by their ability to induce
neutralizing antibodies in experimental animals and to
reduce viremia levels in monkey models. Reduction of
viremia is associated not only with reduced disease severity
at an individual level but also with reduced efficiency of
virus transmission to vector mosquitoes, thus contributing
to reduced infection rates at the population level.
Currently, there are no commercially available dengue
vaccines. However, several types of vaccine have been
developed. Vaccines are considered the most effective
preventive measure and, in addition to their potential contri-
bution to reducing disease in endemic areas, vaccines are
useful for protecting travelers from non-endemic to endemic
countries.
Several lines of epidemiological evidence indicate that
once an individual becomes infected with one type of DENV
they are usually protected from subsequent infection with
the same type of DENV (hereafter referred to as homotypic
infection) [47, 48]. Therefore, humoral and cellular immune
responses to homotypic viral antigens are considered
responsible for protection from subsequent infections and
are therefore the target for induction by protective vaccines.
Viral proteins required for inducing protective immunity
In flavivirus infections, the prM, E and NS1 proteins
are considered important to induce protective immunity. In
a mouse model, immunization with purified E, or passive
administration with monoclonal antibodies to E, induces
protection from lethal infection by the homologous virus,
and the protection correlated with in vitro neutralizing
activity [49–53]. Protective immunity was also rendered in
mice by transferring monoclonal antibodies against prM
[54] or NS1 [55, 56]: antibodies to prM have neutralizing
activity in vitro, but antibodies to NS1 protect mice by a
non-neutralizing mechanism. Based on this knowledge, the
flavivirus prM, E, and/or NS1 genes have been used for
developing genetically engineered dengue vaccines.
Tetravalent formulation
Immunization with a single type of dengue virus
(monovalent vaccine) may present a risk of increased
disease severity upon exposure to later infection with a
different type of dengue virus in endemic areas where more
than one dengue virus type exists, because non-neutralizing
cross-reactive antibodies and cross-reactive memory T
lymphocytes are potential mechanisms to cause dengue
hemorrhagic fever. By contrast, people once infected with a
certain type of dengue virus are usually protected from a
subsequent homotypic infection [47, 48]. Therefore, a
combination of vaccines that can induce immune responses
against all four types of dengue virus (tetravalent vaccine)
would be highly desirable for developing a safe and effec-
tive dengue vaccine [3–10].
Vaccine development
Traditional attenuation: Live attenuated vaccines are
considered the most economical strategy and are therefore
affordable in endemic areas comprised mainly of develop-
ing countries. Two tetravalent vaccine candidates have been
separately developed; at the Mahidol University of Thailand
and at the Walter Reed Army Institute of Research in the
USA. Both vaccine viruses were developed by sequential
passage through primary dog kidney cells, primary green
monkey kidney cells or fetal rhesus lung cells. The vaccine
candidate developed in Thailand has been licensed to
Aventis Pasteur and that developed in the United States to
GlaxoSmithKline.
Both attenuated vaccines have produced high serocon-
version rates to all four serotypes after two or three doses in
clinical trials [57–61], but concerns have been raised about
the interference in virus replication, which is a potential
problem that may occur when infectious vaccines are
combined. Such interference is of particular concern in the
development of dengue tetravalent vaccines, since im-
balanced immune responses may cause increased disease
severity [62]. Therefore, dosage formulations and/or vaccine
schedules are considered important to adjust the immuno-
genicity of the four different live vaccine components [63,
64]. Because of this problem, and issues relating to reacto-
genicity, further clinical trials of the Aventis Pasteur vaccine
candidate have been halted. The phase II trial for evaluating
the GlaxoSmithKline vaccine using a protocol involving
“formulation17” has demonstrated less reactivity in volun-
teers [65]. Tetravalent neutralizing antibody responses were
achieved in 63% of volunteers after two doses, and this66 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
vaccine candidate will proceed to a phase IIb trial.
Chimera: Advances in gene engineering technology have
enabled the construction of chimeric viruses in which
specific proteins from one virus are substituted for those of
another virus. For dengue vaccine candidates, chimeric
viruses have been constructed by exchanging the prM/E
genes of each of DENV1–4 for homologous genes of the
yellow fever virus (YFV) strain 17D [66], or the DENV2
vaccine strain developed by Mahidol University included
in the live-attenuated vaccine described above [67]. The
former was licensed by Sanofi Pasteur and the latter by
InViragen.
The chimeric tetravalent vaccine using YFV strain
17D as a backbone virus was well tolerated and produced
high levels of neutralizing antibodies against DENV1–4
and/or viremia protection following challenge in preclinical
evaluations using non-human primates [68–70] and a phase
I clinical trial [71]. Phase II trials are currently underway in
several countries and a phase III trial has started in Austra-
lia. Another chimeric tetravalent vaccine using a DENV2
vaccine strain as a backbone was also immunogenic and
protective in AG129 mice [72]. A phase I trial is ongoing
for this vaccine strain. Although the chimerization strategy
appears to produce an ideal vaccine, the possibility of
genetic recombination with virulent viruses remains a
concern [62, 73].
Attenuation by deletion at the 3'-UTR: The 3'-UTR is
critical for RNA replication. A 30-nucleotide deletion at
the 3' site (nucleotides 172–143) resulted in attenuation but
retained immunogenicity of DENV4 in monkeys [74]. This
DENV4Δ30 vaccine was also well tolerated and immuno-
genic in humans [75, 76]. The same strategy was successful
in attenuating DENV1 [77, 78], but not DENV2 [79] or
DENV3 [80]. For DENV2 and DENV3, a chimerization
strategy similar to that described above was implemented:
DENV4Δ30 was used as the backbone virus and the prM
and E genes of DENV2 and DENV3 were replaced with
those of DENV4Δ30. Experiments in monkeys indicated
that the tetravalent formulation composed of these geneti-
cally engineered viruses was safe and induced balanced
immune responses [81]. For DENV3, another strategy using
a full-length infectious clone containing two deletions in
the 3'-UTR or the entire 3'-UTR derived from DENV4Δ30
was implemented [82]. Moreover, DENV4Δ30 was further
attenuated and proven to be safe and immunogenic in phase
I clinical evaluations [83, 84]. These vaccine candidates
were licensed by Panacea Biotec Ltd. and Biological E. Ltd.
in India, Vabiotech in Vietnam and the Butantan Foundation
in Brazil.
Viremia levels were low or undetectable in vaccinated
volunteers, and the virus was not transmitted to mosquitoes.
This engineered attenuated vaccine candidate also showed
less propagation in mosquitoes, potentially reducing trans-
mission efficiency. However, a potential concern remained
that immunocompromised individuals, who may be included
in a large population of vaccinees, could experience high-
level viremia and that different geographical strains of
mosquitoes may have different vector competences.
Concerns for inducing enhancing antibodies
Enhancing antibodies are one mechanism for increasing
disease severity. In vitro studies have demonstrated that
neutralizing antibodies that show no enhancing activity at
low serum concentration show enhancing activities at high
concentration [85]. The explanation for this phenomenon is
that neutralizing activities overcome enhancing ones at low
concentrations, although enhancing activities still exist.
Specifically, neutralizing antibodies are usually measured
by conventional neutralization tests using cells such as Vero
or BHK cells. Since these cells do not have FcγRs, these
tests only reflect the neutralizing activity in the serum
samples. On the other hand, conventional ADE assays using
FcγR-bearing cells represent enhancing activities in a range
of serum dilutions where the effect of neutralizing activity
is negligible (subneutralizing doses).
This phenomenon is observed with immune sera and
most monoclonal antibodies [86, 87]. Serum contains
polyclonal antibodies comprising different antibody species.
Some antibody species may have neutralizing activities,
while others may have enhancing activities. Thus, the
balance of neutralizing and enhancing activities is important
for understanding the immune status of the host. However,
conventional neutralization tests using cells without FcγRs
can only detect neutralizing activities included in the serum
sample. The evaluation of vaccine candidates has mostly
been performed using neutralization tests rather than ADE
assays. However, there are concerns that the current vaccine
candidates capable of inducing neutralizing antibodies can
also induce enhancing antibodies. It is highly probable that
neutralizing antibodies constitute an immunological correlate
against DENV, although this is still a subject of debate [45].
This balance of neutralizing and enhancing activities
can be evaluated in a system that uses a BHK-21 cell line
engineered to express FcγR [88] or a K562 cell line adapted
to adhere to a plastic surface [89]. These cells can be used
in an assay system similar to the conventional neutralization
test. However, these cells can detect the enhancing, as well
as the neutralizing, activities in the serum samples because
of the FcγR on their surface. The balance of neutralizing
and enhancing activities in the serum samples can also be
measured in vivo, in a suitable animal model producing
viremia following challenge.67 E. Konishi
Animal model
Intracerebral inoculation of DENV has been the con-
ventional method for evaluating the efficacy of candidate
dengue vaccines in mice. In this method, the clinical
symptoms related to encephalitis, and death, were monitored
[90]. Adult mice are not usually susceptible to peripheral
challenge with DENV, and therefore, fail to develop viremia
following challenge [91–93]. A/J mice developed paralysis
following intravenous infection with high-titer DENV2, but
viremia was limited on day 2 after infection, as determined
by the detection of viral RNA [94]. Severe combined
immunodeficient mice engrafted with human cells susceptible
to DENV infection produced viremia that could be detected
by infectivity [95–98]. Other immunodeficient mouse models
[99–107] have been developed, including AG129 mice
deficient in interferon (IFN)-α/β and IFN-γ receptors [108].
However, the major problem with these models is the lack
of a normal immune response, making vaccine evaluation
difficult, although they are useful for investigating the
pathogenesis of dengue disease and for developing antiviral
agents [109, 110].
Non-human primates are the most reliable animal
models in which to evaluate the efficacy of candidate
dengue vaccines, although they only develop low levels of
viremia for short periods compared with the viremia that
occurs in humans. The induction of neutralizing antibodies
and the reduction in viremia levels can be used as indicators
of vaccine efficacy, but monkeys exhibit only some of the
symptoms of dengue disease observed in humans. Never-
theless, non-human primate models are still being developed
and optimized as preclinical dengue vaccine evaluation
systems [111, 112].
CONCLUSION
Dengue vaccine candidates that can induce neutralizing
antibodies have been developed based on several strategies.
Some of these vaccines are currently undergoing clinical
trials. However, since neutralizing antibodies display
enhancing activities at subneutralizing doses in vitro, there
is a concern that dengue vaccine candidates that induce
neutralizing antibodies may also induce enhancing activities.
Thus, careful evaluation of candidate dengue vaccines is
essential to monitor potential enhancing activities. Further
optimization may be required to reduce such unwanted
activities.
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